ULBI Should I Buy
-
$
0.000
0.000(0.000%)
At close0.000(0.000%)Aft-market
ET
Loading...
Ultralife Corp (ULBI) is not a strong buy for a beginner investor with a long-term strategy at this time. Despite a 21.51% YoY revenue increase in Q3 2025, the company's financial performance is concerning, with significant drops in net income, EPS, and gross margin. Technical indicators suggest a bearish trend, and there are no strong positive catalysts or trading signals to support immediate investment. Given the lack of recent news, analyst ratings, and influential trading activity, it is prudent to hold off on investing until clearer positive signals emerge.
The technical indicators for ULBI suggest a bearish trend. The MACD histogram is negative (-0.071) and contracting, RSI is neutral at 29.399, and moving averages are bearish (SMA_200 > SMA_20 > SMA_5). The stock is trading near its support levels (S1: 5.781, S2: 5.6), with resistance levels at R1: 6.37 and R2: 6.551.
The company's revenue increased by 21.51% YoY in Q3 2025.
Net income dropped significantly by -572.87% YoY, EPS fell by -450.00% YoY, and gross margin declined by -8.80% YoY. Technical indicators are bearish, and there are no significant trading trends or recent news to drive positive sentiment.
In Q3 2025, Ultralife Corp's revenue increased to $43,371,000 (up 21.51% YoY). However, net income dropped to -$1,220,000 (down -572.87% YoY), EPS fell to -0.07 (down -450.00% YoY), and gross margin decreased to 22.18% (down -8.80% YoY).
No data available for analyst ratings or price target changes.
